SCHEMBL2366477

SCHEMBL2366477

Cc1cc(N2CCOC2=O)ccc1C(=O)N1CCN(c2ncc(C#N)cc2C)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 2/20 0.40
EGLN1 Q9GZT9 1/20 0.37
LMNA P02545 3/20 0.36
HTT P42858 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 3/20 0.36
CETP P11597 1/20 0.36
TP53 P04637 4/20 0.36
ALDH1A1 P00352 4/20 0.36
THRB P10828 2/20 0.36
GAA P10253 1/20 0.36
CLK1 P49759 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PIK3CA P42336 2/20 0.36
MTOR P42345 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
SLC6A9 P48067 2/20 0.36
SLC6A5 Q9Y345 2/20 0.36
GBA1 P04062 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366595 0.92 HTT (0.42) KCNJ1LMNAHTTKDM4ECETP
SCHEMBL2365724 0.88 LMNA (0.43) LMNAHTTSMN1; SMN2KDM4ETP53
SCHEMBL2366954 0.85 CFTR (0.40) LMNAHTTSMN1; SMN2KDM4ETP53
SCHEMBL2365697 0.85 KMT2A (0.39) LMNAHTTSMN1; SMN2KDM4ETP53
SCHEMBL2365729 0.84 LMNA (0.36) LMNAHTTSMN1; SMN2KDM4ETP53
SCHEMBL2366044 0.84 EGLN1 (0.47) EGLN1
SCHEMBL2366002 0.83 KCNJ1 (0.38) KCNJ1EGLN1LMNAHTTSMN1; SMN2
SCHEMBL2365996 0.83 KCNJ1 (0.38) KCNJ1EGLN1LMNAHTTSMN1; SMN2
SCHEMBL2366227 0.83 TP53 (0.40) LMNAHTTSMN1; SMN2KDM4ETP53
SCHEMBL2366011 0.81 LMNA (0.42) LMNAHTTSMN1; SMN2KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 KCNJ1 3274/4885EGLN1 128/4885LMNA 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.